Pages that link to "Q28307762"
Jump to navigation
Jump to search
The following pages link to Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes (Q28307762):
Displaying 50 items.
- Targeting of MAPK-associated molecules identifies SON as a prime target to attenuate the proliferation and tumorigenicity of pancreatic cancer cells (Q21245757) (← links)
- K-ras mutational status in cytohistological tissue as a molecular marker for the diagnosis of pancreatic cancer: a systematic review and meta-analysis (Q21284688) (← links)
- Analysis of K-ras and p53 mutations in mesotheliomas from humans and rats exposed to asbestos (Q23924238) (← links)
- Pancreatic cancer (Q24170403) (← links)
- Deregulated expression of KRAP, a novel gene encoding actin-interacting protein, in human colon cancer cells (Q24301816) (← links)
- Cloning of a new Kunitz-type protease inhibitor with a putative transmembrane domain overexpressed in pancreatic cancer (Q24321514) (← links)
- Cloning of novel transcripts of the human guanine-nucleotide-exchange factor Mss4: in situ chromosomal mapping and expression in pancreatic cancer (Q24322681) (← links)
- Evidence for a telomere-independent "clock" limiting RAS oncogene-driven proliferation of human thyroid epithelial cells (Q24552563) (← links)
- Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA (Q24568308) (← links)
- Analysis of the genome to personalize therapy for melanoma (Q24601008) (← links)
- Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma (Q24619532) (← links)
- Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma (Q24627664) (← links)
- Analysis of RAS oncogene mutations in human lymphoid malignancies (Q24643802) (← links)
- Pancreatic cancer: pathogenesis, prevention and treatment (Q24670990) (← links)
- Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination (Q24678848) (← links)
- Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer (Q24685746) (← links)
- Characterization of mutations and loss of heterozygosity of p53 and K-ras2 in pancreatic cancer cell lines by immobilized polymerase chain reaction (Q24794417) (← links)
- p8 inhibits the growth of human pancreatic cancer cells and its expression is induced through pathways involved in growth inhibition and repressed by factors promoting cell growth (Q24797943) (← links)
- Implications of growth factor alterations in the treatment of pancreatic cancer (Q24800145) (← links)
- Genetic alterations in pancreatic carcinoma (Q24801465) (← links)
- Regular use of aspirin and pancreatic cancer risk (Q24801805) (← links)
- What is the origin of pancreatic adenocarcinoma? (Q24805751) (← links)
- Intercalated duct cell is starting point in development of pancreatic ductal carcinoma? (Q24812935) (← links)
- The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer (Q26738873) (← links)
- Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids (Q26739062) (← links)
- The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma (Q26744298) (← links)
- Clinical Applications of NanoVelcro Rare-Cell Assays for Detection and Characterization of Circulating Tumor Cells (Q26744828) (← links)
- FAK and paxillin, two potential targets in pancreatic cancer (Q26765360) (← links)
- Reactive Oxygen Species and Targeted Therapy for Pancreatic Cancer (Q26765827) (← links)
- MEK and PI3K inhibition in solid tumors: rationale and evidence to date (Q26775573) (← links)
- Molecular detection of pancreatic neoplasia: Current status and future promise (Q26777379) (← links)
- Genomic alterations in pancreatic cancer and their relevance to therapy (Q26781443) (← links)
- GEMMs as preclinical models for testing pancreatic cancer therapies (Q26781848) (← links)
- Multifocal intraductal tubulopapillary neoplasm of the pancreas with total pancreatectomy: report of a case and review of literature (Q26783424) (← links)
- Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer (Q26785691) (← links)
- Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles (Q26828959) (← links)
- Impacts of activation of the mitogen-activated protein kinase pathway in pancreatic cancer (Q26830681) (← links)
- Mouse models of pancreatic cancer (Q26860574) (← links)
- Diagnostic accuracy of K-ras mutation for pancreatic carcinoma: a meta-analysis (Q27004523) (← links)
- Pancreatic cancer (Q27005724) (← links)
- The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas (Q27021883) (← links)
- The pancreas cancer microenvironment (Q27026705) (← links)
- Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy (Q27851665) (← links)
- Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma (Q27851677) (← links)
- Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer (Q27851900) (← links)
- Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis? (Q28066454) (← links)
- Genetic factors affecting patient responses to pancreatic cancer treatment (Q28075293) (← links)
- The interplay between obesity and cancer: a fly view (Q28079088) (← links)
- Pancreatic cancer, treatment options, and GI-4000 (Q28083814) (← links)
- Regulation of Cellular Identity in Cancer (Q28086849) (← links)